Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bulk cellular proteins and cell membranes in lesion tissue represent a non-specific therapeutic target for physical or chemical ablative therapies. Rather than binding to a specific receptor, drugs or modalities targeting these components cause widespread denaturation of proteins and disruption of the lipid bilayer (NCBI, 2022). This leads to a loss of cellular integrity and subsequent necrosis of the pathological tissue (StatPearls, 2023). This approach is frequently used in the treatment of localized conditions such as viral warts, actinic keratosis, and certain solid tumors where physical removal of the tissue is desired (PubMed, 2021). Because the mechanism is non-selective, the therapeutic effect is typically restricted to the site of application to prevent damage to healthy surrounding structures (NIH, 2023). Common agents include caustic chemicals like trichloroacetic acid and physical methods like cryotherapy.
Non-specific chemical or physical denaturation of proteins and disruption of lipid membranes leading to coagulative necrosis and tissue destruction (StatPearls, 2023; PubMed, 2021).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bulk cellular proteins and cell membranes in lesion tissue.